Landmark trial finds anal screening prevents cancer
The potentially practice-changing study shows treating precursor lesions reduces cancer in people with HIV
Routine screening and removal of precursor lesions can significantly reduce the risk of anal cancer by nearly 60%, a world-first randomised controlled trial has found.
The finding, from the Anal Cancer-HSIL Outcomes Research (ANCHOR) trial, suggests a test-and-treat approach should be the standard of care for high-risk groups, such as people living with HIV, the researchers say.
